RxDoctor Payments Data

Roy Reardon, MD

Family Medicine · Colquitt, GANPI 1538222393

Payments from drug & device makers

$1,294in general payments, 2019–2025

Across 72 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$294
  • Dexcom, Inc.$238
  • Boehringer Ingelheim$87
  • Lilly USA, LLC$87
  • AstraZeneca$74
  • AbbVie$61
  • plus $455 from 17 others

What the payments were for

  • Food & beverage$1,294100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,294 in reported general payments places this provider in the 60th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$23,217
Medicare patients
29
Services billed
215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate67$47,453
EliquisApixaban123$46,083
CreonLipase/Protease/Amylase19$31,944
FarxigaDapagliflozin Propanediol68$20,113
JardianceEmpagliflozin27$19,904
OzempicSemaglutide15$16,238
MyrbetriqMirabegron17$15,576
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$13,709
XareltoRivaroxaban44$12,717
LinzessLinaclotide22$12,555
MounjaroTirzepatide11$11,167
EntrestoSacubitril/Valsartan11$7,951
InvokanaCanagliflozin26$7,729
RenvelaSevelamer Carbonate14$6,764
TradjentaLinagliptin13$5,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$61$44,49941 claims
Boehringer IngelheimJardiance, Tradjenta$87$25,53940 claims
Johnson & JohnsonXarelto, Invokana$33$20,44670 claims
AstraZenecaFarxiga$74$20,11368 claims
Novo NordiskOzempic$294$16,23815 claims
Astellas Pharma US IncMyrbetriq$36$15,57617 claims
GSKTrelegy Ellipta$18$13,70920 claims
Lilly USA, LLCMounjaro, Humalog$87$11,94724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Colquitt

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →